Top

Published in:

01-10-2016 | Original Article

MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics

Authors: Jessica Oliboni Scapineli, Lucieli Ceolin, Márcia Khaled Puñales, José Miguel Dora, Ana Luiza Maia

Published in: Familial Cancer | Issue 4/2016

Abstract

Multiple endocrine neoplasia type 2A (MEN2A) may be rarely associated with cutaneous lichen amyloidosis (CLA), a skin lesion located in the interescapular region. Here, we describe 3 MEN2A-related CLA kindred and perform a systematic review (SR) of the literature on clinical, biochemical and molecular characteristics of MEN2A-related CLA patients. Thirty-eight patients with MEN2A-related CLA followed at our institution were evaluated. The median age at MEN2A diagnosis in our cohort was 25 (13–41) years, 68 % were women and all harbored codon 634 RET mutations. The literature search resulted in 20 publications that contributed with 25 MEN2A families and 214 individuals. The mean age of MEN2A diagnosis was 31 ± 17 years, with 77 % women. The mean age reported by patients to initial skin lesion suggestive to CLA was 20 ± 13 years. All but two kindred harbored mutations at codon 634: C634R 7 kindred (35 %), C634Y 5 kindred (25 %), C634W 3 kindred (15 %), C634G 1 kindred (5 %), V804M 1 kindred (5 %) and S891A 1 kindred (5 %). Most interesting, the standardized CLA prevalence was higher in women (2.3/1.0, P < 0.005). The overall reported prevalence of medullary thyroid carcinoma, CLA, pheochromocytoma and hyperparathyroidism was 94, 51, 30 and 16 %, respectively. SR of literature indicates that MEN2A-related CLA is more frequent in women and presents a high penetrance, being the second most frequent manifestation of the syndrome, preceded only by MTC.

Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295(18):2164–2167. doi:10.1001/jama.295.18.2164 CrossRefPubMed

Wells SA Jr, Asa SL, Dralle H et al (2015) Revised american thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid Off J Am Thyroid Assoc 25(6):567–610. doi:10.1089/thy.2014.0335 CrossRef

Wells SA Jr, Pacini F, Robinson BG, Santoro M (2013) Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab 98(8):3149–3164. doi:10.1210/jc.2013-1204 CrossRefPubMed

Maia AL, Siqueira DR, Kulcsar MA, Tincani AJ, Mazeto GM, Maciel LM (2014) Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arquivos brasileiros de endocrinologia e metabologia 58(7):667–700CrossRefPubMed

Mathew CG, Chin KS, Easton DF et al (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328(6130):527–528. doi:10.1038/328527a0 CrossRefPubMed

Donis-Keller H, Dou S, Chi D et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2(7):851–856CrossRefPubMed

Mulligan LM, Kwok JB, Healey CS et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363(6428):458–460. doi:10.1038/363458a0 CrossRefPubMed

Punales MK, Graf H, Gross JL, Maia AL (2003) RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab 88(6):2644–2649. doi:10.1210/jc.2002-021422 CrossRefPubMed

Wells SA Jr, Asa SL, Dralle H et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567–610. doi:10.1089/thy.2014.0335 CrossRefPubMedPubMedCentral

10.

Maia AL, Gross JL, Puñales MK (2005) Neoplasia Endócrina Múltipla Tipo 2. Arq Bras Endocrinol Metab 49(5):725–734. doi:10.1590/S0004-27302005000500013 CrossRef

11.

Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA (1989) Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 111(10):802–806CrossRefPubMed

12.

Kousseff BG, Espinoza C, Zamore GA (1991) Sipple syndrome with lichen amyloidosis as a paracrinopathy: pleiotropy, heterogeneity, or a continuous gene? J Am Acad Dermatol 25:651–657CrossRefPubMed

13.

de Groot JWB, Links TP, Plukker JTM, Lips CJM, Hofstra RMW (2006) RET as a diagnostic and therapeutic target in sporadic and hereditary Endocrine tumors. Endocr Rev 27(5):535–560. doi:10.1210/er.2006-0017 CrossRefPubMed

14.

Ferrer JP, Halperin I, Conget JI et al (1991) Primary localized cutaneous amyloidosis and familial medullary thyroid carcinoma. Clin Endocrinol 34(6):435–439CrossRef

15.

Lemos MC, Carrilho F, Rodrigues FJ, Carvalheiro M, Regateiro FJ, Ruas MMA (2003) Caracterização Molecular de uma Família com NEM2A e suas Implicações Clínicas. Acta Méd Port 16:245–250PubMed

16.

Gullu S, Gursoy A, Erdogan MF, Dizbaysak S, Erdogan G, Kamel N (2005) Multiple endocrine neoplasia type 2A/localized cutaneous lichen amyloidosis associated with malignant pheochromocytoma and ganglioneuroma. J Endocrinol Invest 28(8):734–737CrossRefPubMed

17.

Osada D, Viegas SF, Shah MA, Morris RP, Patterson RM (2003) Comparison of different distal radius dorsal and volar fracture fixation plates: a biomechanical study. J Hand Surg 28(1):94–104. doi:10.1053/jhsu.2003.50016 CrossRef

18.

Tanaka A, Arita K, Lai-Cheong JE, Palisson F, Hide M, McGrath JA (2009) New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol 161(6):1217–1224. doi:10.1111/j.1365-2133.2009.09311.x CrossRefPubMed

19.

Breathnach SM (1988) Amyloid and amyloidosis. J Am Acad Dermatol 18(1 Pt 1):1–16CrossRefPubMed

20.

Pacini F, Fugazzola L, Bevilacqua G, Viacava P, Nardini V, Martino E (1993) Multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis: description of a new family. J Endocrinol Invest 16(4):295–296CrossRefPubMed

21.

Verga U, Fugazzola L, Cambiaghi S et al (2003) Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol 59(2):156–161CrossRef

22.

Hong J, Buddenkotte J, Berger TG, Steinhoff M (2011) Management of itch in atopic dermatitis. Semin Cutan Med Surg 30(2):71–86. doi:10.1016/j.sder.2011.05.002 CrossRefPubMedPubMedCentral

23.

Singh DN, Gupta S, Agarwal A (2012) Cutaneous lichen amyloidosis associated with multiple endocrine neoplasia type 2A: an early clinical marker. World J Endocr Surg 4(1):41. doi:10.5005/jp-journals-10002-1092

24.

Rothberg AE, Raymond VM, Gruber SB, Sisson J (2009) Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid Off J Am Thyroid Assoc 19(6):651–655. doi:10.1089/thy.2009.0021 CrossRef

25.

Qi XP, Zhao JQ, Chen ZG et al (2015) RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D. Oncotarget 6(32):33993–34003. doi:10.18632/oncotarget.499 PubMedPubMedCentral

26.

Robinson MF, Furst EJ, Nunziata V et al (1992) Characterization of the clinical features of five families with hereditary primary cutaneous lichen amyloidosis and multiple endocrine neoplasia type 2. Henry Ford Hosp Med J 40(3–4):249–252PubMed

27.

Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, Matsuyama M (1993) Characterization of the ret proto-oncogene products expressed in mouse L cells. Oncogene 8(11):2925–2929PubMed

28.

Lin SF, Huang YY, Lin JD, Chou TC, Hsueh C, Wong RJ (2012) Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS One 7(10):e46726. doi:10.1371/journal.pone.0046726 CrossRefPubMedPubMedCentral

29.

Tamburrino A, Molinolo AA, Salerno P et al (2012) Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res 18(13):3532–3540. doi:10.1158/1078-0432.CCR-11-2700 CrossRefPubMed

30.

Seri M, Celli I, Betsos N, Claudiani F, Camera G, Romeo G (1997) A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. Clin Genet 51(2):86–90CrossRefPubMed

31.

Hofstra RM, Sijmons RH, Stelwagen T et al (1996) RET mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia. J Invest Dermatol 107(2):215–218CrossRefPubMed

32.

Lee DD, Huang JY, Wong CK, Gagel RF, Tsai SF (1996) Genetic heterogeneity of familial primary cutaneous amyloidosis: lack of evidence for linkage with the chromosome 10 pericentromeric region in Chinese families. J Invest Dermatol 107(1):30–33CrossRefPubMed

33.

Birla S, Singla R, Sharma A, Tandon N (2014) Rare manifestation of multiple endocrine neoplasia type 2A & cutaneous lichen amyloidosis in a family with RET gene mutation. Indian J Med Res 139(5):779–781PubMedPubMedCentral

34.

Abdullah F, Udelsman R (2004) Cutaneous lichen amyloidosis in a family with familial medullary thyroid cancer. Surgery 135(5):563–564. doi:10.1016/S0039 CrossRefPubMed

35.

Vieira AE, Mello MP, Elias LL et al (2002) Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A. Horm Metab Res 34(4):202–206. doi:10.1055/s-2002-26712 CrossRefPubMed

36.

Karga HJ, Karayianni MK, Linos DA, Tseleni SC, Karaiskos KD, Papapetrou PD (1998) Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma. Eur J Endocrinol 139(4):410–415CrossRefPubMed

37.

Ceccherini I, Romei C, Barone V et al (1994) Identification of the Cys634– > Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest 17(3):201–204CrossRefPubMed

38.

Nunziata V, Giannattasio R, Di Giovanni G, D’Armiento MR, Mancini M (1989) Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple’s syndrome). Clin Endocrinol 30(1):57–63CrossRef

39.

Donovan DT, Levy ML, Furst EJ et al (1989) Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: a new variant. Henry Ford Hosp Med J 37(3–4):147–150PubMed

Title: MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics
Authors: Jessica Oliboni Scapineli
Lucieli Ceolin
Márcia Khaled Puñales
José Miguel Dora
Ana Luiza Maia
Publication date: 01-10-2016
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2016
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-016-9892-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Identification of a novel PMS2 alteration c.505C>G (R169G) in trans with a PMS2 pathogenic mutation in a patient with constitutional mismatch repair deficiency

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis

Decentralized colonoscopic surveillance with high patient compliance prevents hereditary and familial colorectal cancer

A model for patient-direct screening and referral for familial cancer risk

No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families

Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer